Wolverine Trading, LLC Arrowhead Pharmaceuticals, Inc. Transaction History

Wolverine Trading, LLC

$93.9 Billion
Q3 2024

A detailed history of Wolverine Trading, LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Wolverine Trading, LLC holds 10,500 shares of ARWR stock, worth $205,065. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,500

Previous 7,700 36.36%

Holding current value

$205,065

Previous $200,000 1.5%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$27.21 - $39.48 $601,857 - $873,258	-22,119 Reduced 70.09%	9,441 $270,000
Q4 2023 Feb 14, 2024	BUY	$21.2 - $31.03 $669,072 - $979,306	31,560 New	31,560 $965,000
Q1 2022 May 16, 2022	BUY	$39.62 - $69.97 $228,567 - $403,656	5,769 New	5,769 $263,000
Q2 2020 Aug 13, 2020	SELL	$26.12 - $43.27 $398,225 - $659,694	-15,246 Closed	0 $0
Q1 2020 May 11, 2020	BUY	$20.56 - $63.12 $107,302 - $329,423	5,219 Added 52.05%	15,246 $442,000
Q4 2019 Feb 12, 2020	BUY	$28.14 - $73.01 $67,789 - $175,881	2,409 Added 31.62%	10,027 $644,000
Q3 2019 Nov 14, 2019	SELL	$26.26 - $34.86 $807,600 - $1.07 Million	-30,754 Reduced 80.15%	7,618 $205,000
Q2 2019 Aug 20, 2019	BUY	$17.43 - $28.82 $338,630 - $559,914	19,428 Added 102.55%	38,372 $1.02 Million
Q1 2019 May 15, 2019	SELL	$12.05 - $20.18 $132,706 - $222,242	-11,013 Reduced 36.76%	18,944 $348,000
Q4 2018 Feb 14, 2019	SELL	$10.74 - $19.7 $92,943 - $170,483	-8,654 Reduced 22.41%	29,957 $358,000
Q3 2017 Nov 15, 2017	BUY	$1.69 - $4.33 $65,252 - $167,185	38,611	38,611 $167,000

Others Institutions Holding ARWR

# of Institutions

294

Shares Held

90.8M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.07B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.

Account

Wolverine Trading, LLC Arrowhead Pharmaceuticals, Inc. Transaction History